Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: An open-label, randomised, controlled trial

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 4, 2015, Pages 254-262

  Jia, Weiping ^a   Xiao, Xinhua ^b   Ji, Qiuhe ^c   Ahn, Kyu Jeung ^d   Chuang, Lee Ming ^e   Bao, Yuqian ^a   Pang, Can ^a   Chen, Lei ^a   Gao, Fei ^a   Tu, Yinfang ^a   Li, Pengfei ^f   Yang, Jun ^f  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d Kyung Hee University College of Medicine   (South Korea)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f Lilly Suzhou Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ACARBOSE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INOSITOL; METFORMIN; VOGLIBOSE;

ADULT; ARTICLE; ASIAN; BEDTIME DOSAGE; BOLUS INJECTION; CHINA; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; TAIWAN; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ACARBOSE; AGED; CHINA; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN GLARGINE; INSULIN LISPRO; MALE; METFORMIN; MIDDLE AGED; REPUBLIC OF KOREA; TAIWAN; TREATMENT OUTCOME;

EID: 84925260966     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00041-8     Document Type: Article

References (32)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
2. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
3. Qiao Q, Nakagami T, Tuomilehto J, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000, 43:1470-1475.
4. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
5. Kim SG, Yang SW, Jang AS, et al. Prevalence of diabetes mellitus in the elderly of Namwon County, South Korea. Korean J Intern Med 2002, 17:180-190.
6. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ 1998, 317:371-375. DECODE study group.
7. Pang C, Bao YQ, Wang C, Lu JX, Jia WP, Xiang KS Relationship between the level of fasting plasma glucose and beta cell functions in Chinese with or without diabetes. Chin Med J 2008, 121:2119-2123.
8. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013, 310:948-959.
9. Ji L, Feng B, Su Q, et al. The safety and efficacy of initiating insulin therapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with previous oral antidiabetic drugs. Chin J Diabetes 2011, 19:746-751.
10. China guidance for type 2 diabetes (version 2013). Chin J Diabet Mellitus 2014, 6:447-498. Chinese Medical Association Diabetes Branch.
11. China guidance for type 2 diabetes (version 2007). Chin J Endocrinol Metab 2008, 24:2a-1-23. Chinese Medical Association Diabetes Branch.
12. Federation ID Global guideline for type 2 diabetes (accessed Dec 18, 2014). http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf.
13. Ji L, Jia W, Weng J. Glycemic control in insulinized type 2 diabetes patients in China: one-year results from IDMPS. American Diabetes Association 69th Scientific Sessions, June 5-9, 2009, New Orleans, Louisiana, USA.
14. Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health 2013, 13:602.
15. Guo XH, Yuan L, Lou QQ, et al. A nationwide survey of diabetes education, self-management and glycemic control in patients with type 2 diabetes in China. Chin Med J 2012, 125:4175-4180.
16. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008, 31:20-25.
17. Qu Y, Liu R, Dmitrienko A, Offen W A new classification approach for comparing two active treatments when there is no prior projection on which one is better. Stat Med 2011, 30:3488-3495.
18. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
19. Foster-Powell K, Holt SH, Brand-Miller JC International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 2002, 76:5-56.
20. Elliott P, Stamler J, Dyer AR, et al. Association between protein intake and blood pressure: the INTERMAP Study. Arch Intern Med 2006, 166:79-87.
21. Heise T, Weyer C, Serwas A, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998, 21:800-803.
22. Consensus on the clinical use of premixed insulin. Drug Eval 2013, 10:33-38. Chinese Medical Association Endocrinology Branch.
23. DeFelippis MR, Bakaysa DL, Bell MA, et al. Preparation and characterization of a cocrystalline suspension of [LysB28, ProB29]-human insulin analogue. J Pharm Sci 1998, 87:170-176.
24. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142-2148.
25. Heise T, Heinemann L, Hovelmann U, et al. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and basal-bolus therapy. Diabetes Care 2009, 32:1431-1433.
26. Roach P, Woodworth JR Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002, 41:1043-1057.
27. Hompesch M, Ocheltree SM, Wondmagegnehu ET, et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009, 25:2679-2687.
28. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011, 34:2508-2514.
29. Yang W, Lv X, Li Q, Jia W, Tian H A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Curr Med Res Opin 2012, 28:533-541.
30. Pan C, Yang W, Jia W, Weng J, Tian H Management of Chinese patients with type 2 diabetes, 1998-2006: the Diabcare-China surveys. Curr Med Res Opin 2009, 25:39-45.
31. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab 2012, 14:1081-1087.
32. Peyrot M, Rubin RR, Kruger DF, Travis LB Correlates of insulin injection omission. Diabetes Care 2010, 33:240-245.